نقش اسید های چرب امگا 3 در پیشگیری و درمان بیمار ی کبد چرب غیر الکلی

نوع مقاله : مقاله مروری

نویسندگان

1 دانشجوی کارشناسی ارشد، گروه تغذیه و بیوشیمی، دانشکده‌ی علوم تغذیه و رژیم‌شناسی، دانشگاه علوم پزشکی تهران، تهران، ایران

2 استادیار، گروه تغذیه و بیوشیمی، دانشکده‌ی علوم تغذیه و رژیم‌شناسی، دانشگاه علوم پزشکی تهران، تهران، ایران

3 استادیار، مرکز تحقیقات غدد و متابولیسم، دانشگاه علوم پزشکی اصفهان، اصفهان، ایران

4 استادیار، مرکز تحقیقات تغذیه و امنیت غذایی و گروه تغذیه، دانشکده‌ی بهداشت، دانشگاه علوم پزشکی اصفهان، اصفهان، ایران

چکیده

مقدمه: 35-10 درصد از جمعیت بزرگسالان سراسر جهان به بیماری کبد چرب غیر الکلی مبتلا می‌باشند. تا کنون هیچ درمان قطعی برای این بیماری پیشنهاد نشده است. اسیدهای چرب امگا 3 درای اثرات مفیدی در درمان هایپرلیپیدمی و بیماری‌های قلبی- عروقی می‌باشند و به تازگی برای درمان بیماری کبد چرب غیر الکلی استفاده می‌شوند. هدف از این مطالعه، مرور مطالعاتی بود که نقش اسیدهای چرب امگا 3 در پیشگیری و درمان بیماری کبد چرب غیر الکلی را بررسی کرده بودند.روش‌ها: ابتدا از پایگاه‌های PubMed و ISI مقالاتی که در متن خود دارای کلمات NAFLD (Non-alcoholic fatty liver disease)، NASH (Nonalcoholic steatohepatitis)، Nonalcoholic fatty liver، Steatosis، DHA (Docosahexaenoic acid)، EPA (Eicosapentaenoic acid)، Fish oil و 3Omega  بودند، جستجو شدند. سپس مقالات به سه دسته مطالعات حیوانی، مطالعات مقطعی و مورد- شاهدی و مطالعات کارآزمایی بالینی تقسیم‌بندی شدند که در مجموع، 21 مقاله مورد ارزیابی قرار گرفتند.یافته‌ها: نتایج مطالعات مقطعی و مورد- شاهدی همسو نبود، اما نتایج مطالعات قوی‌تر نشان می‌داد که دریافت ناکافی از منابع غذایی امگا 3 با بروز بیماری کبد چرب در ارتباط می‌باشد. بیشتر مداخلات انجام شده در مطالعات حیوانی و انسانی، تأثیر مثبتی از مصرف مکمل امگا 3 در کاهش تری گلیسیرید و چربی کبدی در مبتلایان به کبد چرب غیر الکلی گزارش کرده‌اند.نتیجه‌گیری: کاهش دریافت امگا 3 از منابع غذایی به دلیل عادات غذایی نادرست، می‌تواند یکی از دلایل چند عاملی بودن بیماری کبد چرب باشد. همچنین مصرف مکمل آن می‌تواند در کنار اصلاح الگوی غذایی و سبک زندگی برای این بیماران مفید باشد.

کلیدواژه‌ها

عنوان مقاله [English]

The Role of Omega-3 Fatty Acids on the Prevention and Treatment of Nonalcoholic Fatty Liver Disease: A Review of Published Papers

نویسندگان [English]

  • Hamid Zolfaghari 1
  • Kourosh Jafarian 2
  • Bijhan Iraj 3
  • Gholamreza Askari 4
1 MSc Student, Department of Nutrition and Biochemistry, School of Nutritional Sciences and Dietetics, Tehran university of Medical Sciences, Tehran, Iran
2 Assistant Professor, Department of Nutrition and Biochemistry, School of Nutritional Sciences and Dietetics, Tehran university of Medical Sciences, Tehran, Iran
3 Assistant Professor, Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
4 Assistant Professor, Food Security Research Center AND Department of Community Nutrition, School of Nutrition and Food Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
چکیده [English]

Background: 10 to 35% of the adult population all round the world is infected with nonalcoholic fatty liver disease (NAFLD). So far, no cure is recommended for this disease. Omega-3 fatty acids have beneficial effects in the treatment of hyperlipidemia and cardiovascular disease; the resort is recently used for the treatment of nonalcoholic fatty liver disease. The aim of this study was to review the studies about the role of omega-3 fatty acids on the prevention and treatment of nonalcoholic fatty liver disease.Methods: First, PubMed and ISI databases were searched for the papers in their text there were the words NAFLD, NASH, nonalcoholic fatty liver, steatosis, DHA, EPA, fish oil and omega 3. Then, the papers were divided into tree groups: animal studies, cross-sectional studies, and case-control studies and clinical trials. Totally, 21 articles were evaluated.Findings: The results of cross-sectional and case-control studies were not similar, but more robust studies showed that inadequate intakes of dietary sources of omega-3 was associated with fatty liver disease. Most interventions have been conducted in animal and human studies that have been reported positive effects of omega-3 supplementation in reducing triglycerides and fatty liver in patients with nonalcoholic fatty liver.Conclusion: According to the available evidence, it seems that reduction of omega-3 food sources due to poor eating habits can be one of the reasons of multi-factorial fatty liver disease. In addition, the use of omega-3 supplement along with modification of the diet pattern and lifestyle is beneficial for patients.

کلیدواژه‌ها [English]

  • Non-Alcoholic Fatty Liver Disease
  • Predicting
  • Omega-3
  • Docosahexaenoic acid
  • Eicosapentaenoic acid

مراجع

  1. McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin Liver Dis 2004; 8(3): 521-33, viii.
  2. Hegazi RA, Sutton-Tyrrell K, Evans RW, Kuller LH, Belle S, Yamamoto M, et al. Relationship of adiposity to subclinical atherosclerosis in obese patients with type 2 diabetes. Obes Res 2003; 11(12): 1597-605.
  3. Malaguarnera L, Di RM, Zambito AM, dell'Ombra N, Di MR, Malaguarnera M. Potential role of chitotriosidase gene in nonalcoholic fatty liver disease evolution. Am J Gastroenterol 2006; 101(9): 2060-9.
  4. Malaguarnera L, Di RM, Zambito AM, dell'Ombra N, Nicoletti F, Malaguarnera M. Chitotriosidase gene expression in Kupffer cells from patients with non-alcoholic fatty liver disease. Gut 2006; 55(9): 1313-20.
  5. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114(4): 842-5.
  6. Malaguarnera M, Vacante M, Motta M, Malaguarnera M, Li VG, Galvano F. Effect of L-carnitine on the size of low-density lipoprotein particles in type 2 diabetes mellitus patients treated with simvastatin. Metabolism 2009; 58(11): 1618-23.
  7. Galvano F, Li VG, Malaguarnera M, Avitabile T, Antic T, Vacante M, et al. Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus. Expert Opin Pharmacother 2009; 10(12): 1875-82.
  8. Unger RH, Orci L. Lipoapoptosis: its mechanism and its diseases. Biochim Biophys Acta 2002; 1585(2-3): 202-12.
  9. Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R, et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005; 54(12): 3541-6.
  10. Shimabukuro M, Zhou YT, Levi M, Unger RH. Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci U S A 1998; 95(5): 2498-502.
  11. de Almeida IT, Cortez-Pinto H, Fidalgo G, Rodrigues D, Camilo ME. Plasma total and free fatty acids composition in human non-alcoholic steatohepatitis. Clin Nutr 2002; 21(3): 219-23.
  12. Yki-Jarvinen H. Nutritional modulation of nonalcoholic fatty liver disease and insulin resistance: human data. Curr Opin Clin Nutr Metab Care 2010; 13(6): 709-14.
  13. Bedogni G, Bellentani S. Fatty liver: how frequent is it and why? Ann Hepatol 2004; 3(2): 63-5.
  14. Shapiro H, Tehilla M, Attal-Singer J, Bruck R, Luzzatti R, Singer P. The therapeutic potential of long-chain omega-3 fatty acids in nonalcoholic fatty liver disease. Clin Nutr 2011; 30(1): 6-19.
  15. Henkel J, Frede K, Schanze N, Vogel H, Schurmann A, Spruss A, et al. Stimulation of fat accumulation in hepatocytes by PGE(2)-dependent repression of hepatic lipolysis, beta-oxidation and VLDL-synthesis. Lab Invest 2012; 92(11): 1597-606.
  16. Owen JL, Zhang Y, Bae SH, Farooqi MS, Liang G, Hammer RE, et al. Insulin stimulation of SREBP-1c processing in transgenic rat hepatocytes requires p70 S6-kinase. Proc Natl Acad Sci U S A 2012; 109(40): 16184-9.
  17. Zhang J, Tan Y, Yao F, Zhang Q. Polydatin alleviates non-alcoholic fatty liver disease in rats by inhibiting the expression of TNF-alpha and SREBP-1c. Mol Med Rep 2012; 6(4): 815-20.
  18. Porter JR, Lee CY, Espenshade PJ, Iglesias PA. Regulation of SREBP during hypoxia requires Ofd1-mediated control of both DNA binding and degradation. Mol Biol Cell 2012; 23(18): 3764-74.
  19. Akarte AS, Srinivasan BP, Gandhi S. Vildagliptin selectively ameliorates GLP-1, GLUT4, SREBP-1c mRNA levels and stimulates beta-cell proliferation resulting in improved glucose homeostasis in rats with streptozotocin-induced diabetes. J Diabetes Complications 2012; 26(4): 266-74.
  20. Yahagi N, Shimano H, Hasty AH, Amemiya-Kudo M, Okazaki H, Tamura Y, et al. A crucial role of sterol regulatory element-binding protein-1 in the regulation of lipogenic gene expression by polyunsaturated fatty acids. J Biol Chem 1999; 274(50): 35840-4.
  21. Shao W, Espenshade PJ. Expanding roles for SREBP in metabolism. Cell Metab 2012; 16(4): 414-9.
  22. Levy JR, Clore JN, Stevens W. Dietary n-3 polyunsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats. Hepatology 2004; 39(3): 608-16.
  23. Svegliati-Baroni G, Candelaresi C, Saccomanno S, Ferretti G, Bachetti T, Marzioni M, et al. A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury. Am J Pathol 2006; 169(3): 846-60.
  24. Buettner R, Parhofer KG, Woenckhaus M, Wrede CE, Kunz-Schughart LA, Scholmerich J, et al. Defining high-fat-diet rat models: metabolic and molecular effects of different fat types. J Mol Endocrinol 2006; 36(3): 485-501.
  25. Shirouchi B, Nagao K, Inoue N, Ohkubo T, Hibino H, Yanagita T. Effect of dietary omega 3 phosphatidylcholine on obesity-related disorders in obese Otsuka Long-Evans Tokushima fatty rats. J Agric Food Chem 2007; 55(17): 7170-6.
  26. Sekiya M, Yahagi N, Matsuzaka T, Najima Y, Nakakuki M, Nagai R, et al. Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression. Hepatology 2003; 38(6): 1529-39.
  27. El-Badry AM, Moritz W, Contaldo C, Tian Y, Graf R, Clavien PA. Prevention of reperfusion injury and microcirculatory failure in macrosteatotic mouse liver by omega-3 fatty acids. Hepatology 2007; 45(4): 855-63.
  28. Martin PG, Guillou H, Lasserre F, Dejean S, Lan A, Pascussi JM, et al. Novel aspects of PPARalpha-mediated regulation of lipid and xenobiotic metabolism revealed through a nutrigenomic study. Hepatology 2007; 45(3): 767-77.
  29. Gonzalez-Periz A, Horrillo R, Ferre N, Gronert K, Dong B, Moran-Salvador E, et al. Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J 2009; 23(6): 1946-57.
  30. Capristo E, Miele L, Forgione A, Vero V, Farnetti S, Mingrone G, et al. Nutritional aspects in patients with non-alcoholic steatohepatitis (NASH). Eur Rev Med Pharmacol Sci 2005; 9(5): 265-8.
  31. Cortez-Pinto H, Jesus L, Barros H, Lopes C, Moura MC, Camilo ME. How different is the dietary pattern in non-alcoholic steatohepatitis patients? Clin Nutr 2006; 25(5): 816-23.
  32. Toshimitsu K, Matsuura B, Ohkubo I, Niiya T, Furukawa S, Hiasa Y, et al. Dietary habits and nutrient intake in non-alcoholic steatohepatitis. Nutrition 2007; 23(1): 46-52.
  33. Zelber-Sagi S, Nitzan-Kaluski D, Goldsmith R, Webb M, Blendis L, Halpern Z, et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol 2007; 47(5): 711-7.
  34. Kim CH, Kallman JB, Bai C, Pawloski L, Gewa C, Arsalla A, et al. Nutritional assessments of patients with non-alcoholic fatty liver disease. Obes Surg 2010; 20(2): 154-60.
  35. Shi L, Liu ZW, Li Y, Gong C, Zhang H, Song LJ, et al. The prevalence of nonalcoholic fatty liver disease and its association with lifestyle/dietary habits among university faculty and staff in Chengdu. Biomed Environ Sci 2012; 25(4): 383-91.
  36. Capanni M, Calella F, Biagini MR, Genise S, Raimondi L, Bedogni G, et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther 2006; 23(8): 1143-51.
  37. Itoh M, Suganami T, Satoh N, Tanimoto-Koyama K, Yuan X, Tanaka M, et al. Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects. Arterioscler Thromb Vasc Biol 2007; 27(9): 1918-25.
  38. Spadaro L, Magliocco O, Spampinato D, Piro S, Oliveri C, Alagona C, et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis 2008; 40(3): 194-9.
  39. Tanaka N, Sano K, Horiuchi A, Tanaka E, Kiyosawa K, Aoyama T. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol 2008; 42(4): 413-8.
  40. Sofi F, Giangrandi I, Cesari F, Corsani I, Abbate R, Gensini GF, et al. Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-alcoholic fatty liver disease patients: a preliminary study. Int J Food Sci Nutr 2010; 61(8): 792-802.
  41. Nobili V, Bedogni G, Alisi A, Pietrobattista A, Rise P, Galli C, et al. Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch Dis Child 2011; 96(4): 350-3.
مجله دانشکده پزشکی اصفهان
دوره 32، شماره 276 - شماره پیاپی 276
فروردین و اردیبهشت 1393
صفحه 243-255

فایل ها

سابقه مقاله

  • تاریخ دریافت: 21 خرداد 1392
  • تاریخ بازنگری: 11 آبان 1403
  • تاریخ پذیرش: 17 فروردین 1401

هم رسانی

ارجاع به این مقاله

آمار